Goldman Sachs Maintains Neutral on Revance Therapeutics, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Chris Shibutani has maintained a Neutral rating on Revance Therapeutics (RVNC) and lowered the price target from $9 to $8.
May 13, 2024 | 3:52 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs has maintained its Neutral rating on Revance Therapeutics but reduced the price target from $9 to $8.
The reduction in price target by a prominent analyst like Goldman Sachs can lead to negative investor sentiment in the short term, potentially causing a decrease in RVNC's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100